Prophylactic amnioinfusion in preganancies complicated by chorioamnionitis: a prospective randomized trial.
The objective of this article is to prospectively investigate the efficacy of amnioinfusion as a means to reduce febrile morbidity in pregnancies complicated by chorioamnionitis. All laboring patients with a temperature > or =100.1 degrees F were approached for study participation. Exclusion criteria included amnionitis diagnosed at greater than 8 cm dilation, multiple gestation, placental abruption, or a nonreassuring fetal heart rate tracing. Consenting patients were randomized to receive antibiotics (ampicillin or penicillin with gentamicin) and acetaminophen with or without amnioinfusion. All patients received intrauterine pressure catheter placement. For study patients, normal saline at room temperature was infused at 10 mL/min for 60 min, then 3 mL/min until delivery. Postpartum endometritis was defined as a temperature = 100.4 degrees F accompanied by uterine tenderness more than 12 hr after delivery. Statistical analysis was performed using the Student's t-test for continuous data and Chi-square for discrete variables. Thirty-six patients were enrolled, and complete data were available for 34 patients (17 in each group). There were no differences between groups with respect to maternal age, gravidity, race, or gestational age. There were also no differences between groups in duration of rupture of membranes, temperature at randomization, interval from randomization to delivery, cesarean section rate, or umbilical cord arterial pH. The mean temperature at the time of delivery was 99.8+/-0.9 degrees F for the amnioinfusion group versus 100.5+/-1.0 degrees F for the control group (p=0.046). Three of 17 amnioinfusion patients and 3 of 17 control patients had postpartum endometritis. There was 1 neonatal infection in the treatment group and no neonatal infections among the control patients. Prophylactic amnioinfusion was associated with a decline in temperature at the time of delivery. No untoward effects from the amnioinfusion were identified.
Parilla
B V
BV
Department of Obstetrics and Gynecology, Northwestern University Medical School and Northwestern Memorial Hospital, Chicago, Illinois, USA.
McDermott
T M
TM
D000328:Adult; D000650:Amnion; D000900:Anti-Bacterial Agents; D016009:Chi-Square Distribution; D002821:Chorioamnionitis / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D004716:Endometritis / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D005260:Female; D005334:Fever / Q000209:etiology / Q000628:therapy; D005440:Fluid Therapy; D006801:Humans; D007263:Infusions, Parenteral; D007267:Injections; D049590:Postpartum Period; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000628:therapy*; D011256:Pregnancy Outcome; D011322:Primary Prevention / Q000379:methods; D011446:Prospective Studies; D012965:Sodium Chloride / Q000008:administration & dosage; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D012965:Sodium Chloride